Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [Pediatric Oncology]
Conclusion
Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort from pooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Weigel, Lyden, Anderson, Meyer, Parham, Rodeberg, Michalski, Hawkins, Arndt Tags: Rhabdomyosarcoma & Soft Tissue Sarcoma, Chemotherapy, Rhabdo & Other Soft Tissue Sarcomas: Pediatric Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Children | History of Medicine | Pediatrics | Radiation Therapy | Rhabdomyosarcoma | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology